相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brain metastases: The HER2 paradigm
Nancy U. Lin et al.
CLINICAL CANCER RESEARCH (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
David M. Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma
Edgardo Rivera et al.
CANCER (2006)
Temozolomide in metastatic breast cancer (MBC): A phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG)
ME Trudeau et al.
ANNALS OF ONCOLOGY (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
AMP Omuro et al.
CANCER (2005)
Effects of the EGFR/HER2 kinase inhibitor gw572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance
H Zhou et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Gefitinib in patients with brain metastases from non-small-cell lung cancer:: a prospective trial
GL Ceresoli et al.
ANNALS OF ONCOLOGY (2004)
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
HJ Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Breast cancer teams: the impact of constitution, new cancer workload, and methods of operation on their effectiveness
R Haward et al.
BRITISH JOURNAL OF CANCER (2003)
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
JC Bendell et al.
CANCER (2003)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
